Seattle Genetics, Astellas snag quick FDA approval for bladder cancer-fighter Padcev

Historically, metastatic bladder cancer has been “a very bad prognosis,” in the words of Seattle Genetics CEO Clay Siegall. But his company and partner Astellas now have a shot at trying to change that. Wednesday, the FDA approved Padcev, a first-of-its kind antibody drug conjugate.